Published in J Clin Invest on April 01, 1993
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis (2008) 3.17
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
Sleep loss and inflammation. Best Pract Res Clin Endocrinol Metab (2010) 1.69
C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract (2009) 1.66
Diagnostic markers of infection in neonates. Arch Dis Child Fetal Neonatal Ed (2004) 1.54
Newer approaches to the diagnosis of early onset neonatal sepsis. Arch Dis Child Fetal Neonatal Ed (2006) 1.47
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47
Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care (2003) 1.46
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
C reactive protein levels are increased in non-allergic but not allergic asthma: a multicentre epidemiological study. Thorax (2005) 1.33
C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care (2011) 1.31
Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res (2012) 1.29
Systemic inflammation and lung function in young adults. Thorax (2007) 1.23
Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol (2003) 1.21
Pattern recognition by pentraxins. Adv Exp Med Biol (2009) 1.19
Usefulness of C-reactive protein in monitoring the severe community-acquired pneumonia clinical course. Crit Care (2007) 1.19
Iron status of inner-city African-American infants. Am J Hematol (2007) 1.16
Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem (2008) 1.15
Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study. Crit Care (2006) 1.12
Clinical utility of peri-operative C-reactive protein testing in general surgery. Ann R Coll Surg Engl (2008) 1.11
The relation of C--reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol (2010) 1.11
The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo. J Clin Invest (1994) 1.11
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest (1997) 1.07
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli. Clin Exp Immunol (1994) 1.05
Plasma proteome dynamics: analysis of lipoproteins and acute phase response proteins with 2H2O metabolic labeling. Mol Cell Proteomics (2012) 1.05
Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care (2012) 1.00
Increased levels of the inflammatory biomarker C-reactive protein at baseline are associated with childhood sickle cell vasocclusive crises. Br J Haematol (2009) 1.00
Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther (2003) 1.00
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Mol Ther Nucleic Acids (2012) 0.97
Biomarkers for sepsis: a review with special attention to India. Biomed Res Int (2014) 0.97
Effects of particulate matter on inflammatory markers in the general adult population. Part Fibre Toxicol (2012) 0.94
Role of C-reactive protein in complement-mediated hemolysis in Malaria. Glycoconj J (2006) 0.93
Collagen-induced arthritis is exacerbated in C-reactive protein-deficient mice. Arthritis Rheum (2011) 0.92
Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensive Care (2012) 0.92
Persistent endothelial activation and inflammation after Plasmodium falciparum Infection in Malawian children. J Infect Dis (2013) 0.91
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One (2013) 0.88
Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia. Clin Exp Immunol (2006) 0.88
The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep (2007) 0.88
Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study. Eur J Epidemiol (2007) 0.87
Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm (2012) 0.87
An association between the acute phase response and patterns of antigen induced T cell proliferation in juvenile idiopathic arthritis. Arthritis Res Ther (2003) 0.86
C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol (2014) 0.86
Serum levels of proinflammatory cytokines in painful knee osteoarthritis and sensitization. Int J Inflam (2015) 0.84
Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia [ISRCTN31976779]. Crit Care (2006) 0.83
The C-Reactive Protein/Albumin Ratio as an Independent Predictor of Mortality in Patients with Severe Sepsis or Septic Shock Treated with Early Goal-Directed Therapy. PLoS One (2015) 0.82
Sensitivity and specificity of C-reactive protein and α(1) -acid glycoprotein for episodes of acute infection among children in Kilimanjaro, Tanzania. Am J Hum Biol (2012) 0.81
Interpretation of C-reactive protein concentrations in critically ill patients. Biomed Res Int (2013) 0.81
Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLoS One (2013) 0.81
Links among inflammation, sexual activity and ovulation: Evolutionary trade-offs and clinical implications. Evol Med Public Health (2015) 0.81
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods (2012) 0.81
Novel diagnostics for aggravating pancreatic fistulas at the acute phase after pancreatectomy. World J Gastroenterol (2014) 0.80
The influence of type 2 diabetes mellitus on the expression of inflammatory mediators and tissue inhibitor of metalloproteinases-2 in human chronic periodontitis. J Periodontal Implant Sci (2011) 0.80
Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomes. Health Qual Life Outcomes (2014) 0.80
Role of C-reactive protein as a marker of disease severity and cardiovascular risk in patients with psoriasis. Indian Dermatol Online J (2015) 0.80
Prospective evaluation of the usefulness of C-reactive protein in the diagnosis of neonatal sepsis in a sub-Saharan African region. Antimicrob Resist Infect Control (2012) 0.79
C-reactive protein, established risk factors and social inequalities in cardiovascular disease - the significance of absolute versus relative measures of disease. BMC Public Health (2008) 0.79
Correlation between hs-CRP and Asthma Control Indices. Tanaffos (2013) 0.79
Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocytes in tuberculosis and Indian visceral leishmaniasis. Glycoconj J (2009) 0.79
Systemic inflammation (C-reactive protein) in type 2 diabetic patients is associated with ambient air pollution in Pune City, India. Diabetes Care (2012) 0.79
Targeting C-reactive protein levels using high-dose atorvastatin before coronary artery bypass graft surgery. Exp Clin Cardiol (2008) 0.78
Solubilization and purification of recombinant modified C-reactive protein from inclusion bodies using reversible anhydride modification. Biophys Rep (2015) 0.78
Skeletal Muscle Insulin Resistance and Absence of Inflammation Characterize Insulin-Resistant Grade I Obese Women. PLoS One (2016) 0.77
Change in cardiovascular risk factors with progression of kidney disease. Am J Nephrol (2008) 0.77
Linkage between C-reactive protein and triglyceride-rich lipoprotein metabolism. Metabolism (2012) 0.77
Mulberry leaf reduces oxidation and C-reactive protein level in patients with mild dyslipidemia. Biomed Res Int (2013) 0.77
Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability. Clin Chem Lab Med (2013) 0.77
Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy Kardiol Interwencyjnej (2014) 0.77
Plasma C-reactive protein and haptoglobin concentrations in critically ill neonatal foals. J Vet Intern Med (2015) 0.76
Energetics and the immune system: Trade-offs associated with non-acute levels of CRP in adolescent Gambian girls. Evol Med Public Health (2016) 0.75
Let her sleep...but how much? Sleep (2009) 0.75
Normal range of the inflammation related laboratory findings and predictors of the postoperative infection in spinal posterior fusion surgery. Clin Orthop Surg (2012) 0.75
Management of neonatal sepsis at Muhimbili National Hospital in Dar es Salaam: diagnostic accuracy of C-reactive protein and newborn scale of sepsis and antimicrobial resistance pattern of etiological bacteria. BMC Pediatr (2014) 0.75
To Evaluate and Compare Periodontal Disease and Smoking as a Parallel Risk Factor for Systemic Health by Gauging the Serum C-Reactive Protein Levels. J Clin Diagn Res (2017) 0.75
Is C-reactive protein the single most useful predictor of difficult laparoscopic cholecystectomy or its conversion? A pilot study. J Minim Access Surg (2016) 0.75
Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol (2016) 0.75
Significant Increase in C-Reactive Protein and Serum Amyloid A in the Early Hours of Paroxysmal Atrial Fibrillation. Cardiol Res (2016) 0.75
Study of High Sensitive C-Reactive Protein (HS-CRP) After Cardiac Rehabilitation Program in Patients Undergoing Isolated CABG. Int J Biomed Sci (2016) 0.75
Human plasma N-glycosylation as analyzed by MALDI-FTICR-MS associates with markers of inflammation and metabolic health. Mol Cell Proteomics (2016) 0.75
Early detection of neonatal group B streptococcus sepsis and the possible diagnostic utility of IL-6, IL-8, and CD11b in a human umbilical cord blood in vitro model. Infect Drug Resist (2016) 0.75
Prediction of the grade of acute cholecystitis by plasma level of C-reactive protein. Iran Red Crescent Med J (2015) 0.75
Studies of the structure and binding properties of hamster female protein. Immunology (1993) 0.75
Potential Use of Salivary Markers for Longitudinal Monitoring of Inflammatory Immune Responses to Vaccination. Mediators Inflamm (2016) 0.75
Review of Prospects of Biological Fluid Biomarkers in Osteoarthritis. Int J Mol Sci (2017) 0.75
C-reactive protein as a pro-inflammatory mediator in cardiovascular disease by its ability to activate complement: additional proof and hypothetical mechanisms. Neth Heart J (2002) 0.75
IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections. PLoS Pathog (2016) 0.75
To Compare the Efficacy of C-Reactive Protein and Total Leucocyte Count as Markers for Monitoring the Course of Odontogenic Space Infections. J Maxillofac Oral Surg (2016) 0.75
Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. Prostate (2017) 0.75
C-reactive protein and the acute phase reaction in geriatric patients. Z Gerontol Geriatr (2015) 0.75
Interleukin-6 and the acute phase response. Biochem J (1990) 7.97
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
C-reactive protein fifty years on. Lancet (1981) 5.93
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Studies of acute phase protein. I. An immunohistochemical method for the localization of Cx-reactive protein in rabbits. Association with necrosis in local inflammatory lesions. J Exp Med (1961) 2.62
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest (1985) 2.21
C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med (1981) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Studies of acute-phase protein. II. Localization of Cx-reactive protein in heart in induced myocardial infarction in rabbits. J Clin Invest (1963) 1.88
Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J Biol Chem (1985) 1.79
Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol (1982) 1.77
Interaction of C-reactive protein with artificial phosphatidylcholine bilayers. Nature (1979) 1.75
Complement activation by C-reactive protein complexes. Ann N Y Acad Sci (1982) 1.75
Binding of C-reactive protein to chromatin and nucleosome core particles. A possible physiological role of C-reactive protein. J Biol Chem (1984) 1.73
Serum amyloid P component is the major calcium-dependent specific DNA binding protein of the serum. Biochem Biophys Res Commun (1987) 1.69
C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J Immunol (1989) 1.66
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet (1988) 1.61
C-reactive protein in SLE. Clin Rheum Dis (1982) 1.61
Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis. Clin Exp Immunol (1981) 1.48
C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol (1985) 1.40
Genomic DNA sequence for human C-reactive protein. J Biol Chem (1985) 1.39
Localizing of C-reactive protein in synovium of patients with rheumatoid arthritis. Arthritis Rheum (1977) 1.38
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med (1988) 1.34
Pentraxin-chromatin interactions: serum amyloid P component specifically displaces H1-type histones and solubilizes native long chromatin. J Exp Med (1990) 1.30
C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med (1987) 1.27
Primary structure of human C-reactive protein. Proc Natl Acad Sci U S A (1977) 1.17
Generation of biologically active C-reactive protein peptides by a neutral protease on the membrane of phorbol myristate acetate-stimulated neutrophils. J Immunol (1989) 1.15
Opsonic properties of C-reactive protein in vivo. J Immunol (1982) 1.13
Studies on vasculitis. VII. C-reactive protein as a substance perpetuating chronic vasculitis. Occurrence in lesions and concentrations in sera. Clin Allergy (1976) 1.09
Real-time measurement of serum C-reactive protein in the management of infection in the elderly. Age Ageing (1986) 1.09
Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization. J Biol Chem (1985) 1.08
C-reactive protein and bacterial infection in preterm infants. Eur J Pediatr (1990) 1.05
Molecular genetics, structure, and function of C-reactive protein. Immunol Res (1991) 1.04
High efficiency iodination of monoclonal antibodies for radiotherapy. J Nucl Med (1987) 1.02
The role of the spleen in the protective effect of C-reactive protein in Streptococcus pneumoniae infection. Clin Exp Immunol (1983) 1.02
Radiometric ligand binding assay for C-reactive protein. Complexed C-reactive protein is not detectable in acute phase serum. Clin Exp Immunol (1982) 0.99
Effects of C-reactive protein on human neutrophil granulocytes challenged with N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor. Life Sci (1989) 0.98
One step preparation of both human C-reactive protein and CIt. FEBS Lett (1978) 0.96
In vivo turnover studies of C-reactive protein. Clin Exp Immunol (1985) 0.96
Human C-reactive protein inhibits neutrophil chemotaxis in vitro: possible implications for the adult respiratory distress syndrome. J Lab Clin Med (1990) 0.95
In vivo studies of serum C-reactive protein turnover in rabbits. J Clin Invest (1983) 0.95
In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit. Clin Exp Immunol (1984) 0.94
Analysis of the binding of C-reactive protein to chromatin subunits. J Immunol (1991) 0.89
Immunohistochemical studies of C-reactive protein and apolipoprotein B in inflammatory and arterial lesions. J Pathol (1985) 0.86
Serum C-reactive protein levels in the management of infection in acute leukaemia. Eur J Cancer Clin Oncol (1984) 0.86
C-reactive protein decreases protein phosphorylation in stimulated human neutrophils. FEBS Lett (1988) 0.85
C-reactive protein in human lattice corneal dystrophy. Curr Eye Res (1983) 0.85
C-reactive protein inhibits binding of platelet-activating factor to human platelets. Thromb Res (1991) 0.85
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol (1997) 7.27
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
C-reactive protein fifty years on. Lancet (1981) 5.93
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature (1997) 5.47
Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. Eur Heart J (2001) 4.21
Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med (1999) 3.88
Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med (1990) 3.17
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Role of complement in induction of the allergic response. Nat New Biol (1972) 2.90
Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature (1993) 2.78
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature (2002) 2.71
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Activation of mouse complement by different classes of mouse antibody. Immunology (1979) 2.68
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care (2000) 2.63
Effect of alcohol consumption on systemic markers of inflammation. Lancet (2001) 2.52
Serum amyloid P-component is an acute-phase reactant in the mouse. Nature (1979) 2.49
Complement dependence of localisation of aggregated IgG in germinal centres. Scand J Immunol (1975) 2.48
Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest (1982) 2.48
Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med (1974) 2.45
Quantitative fecal indium 111-labeled leukocyte excretion in the assessment of disease in Crohn's disease. Gastroenterology (1983) 2.37
Amyloidosis and the respiratory tract. Thorax (1999) 2.36
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum (1997) 2.31
Role of C3 in in vitro lymphocyte cooperation. Nature (1974) 2.27
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Role of complement in the induction of immunological responses. Transplant Rev (1976) 2.21
Analogues in other mammals and in fish of human plasma proteins, C-reactive protein and amyloid P component. Nature (1978) 2.18
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology (1997) 2.18
C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med (1999) 2.17
Isolation of human C-reactive protein and serum amyloid P component. J Immunol Methods (1982) 2.15
Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet (1982) 2.10
Amyloidosis. Histopathology (1994) 2.10
Isolation of amyloid P component (protein AP) from normal serum as a calcium-dependent binding protein. Lancet (1977) 2.09
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Structure of pentameric human serum amyloid P component. Nature (1994) 2.07
Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology (1979) 2.07
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet (1993) 2.00
Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat Med (2001) 1.99
Isolation of C-reactive protein by affinity chromatography. Clin Exp Immunol (1977) 1.97
C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM (2003) 1.93
Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J (1999) 1.87
Three dimensional structure of human C-reactive protein. Nat Struct Biol (1996) 1.87
Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A (1995) 1.83
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Prevalence and significance of the familial Mediterranean fever gene mutation encoding pyrin Q148. QJM (2001) 1.80
Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med (1998) 1.78
A novel variant of transthyretin, 59Thr-->Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation (1995) 1.77
Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses. J Mol Biol (1997) 1.77
Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis (1980) 1.76
Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) (2006) 1.76
Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. Kidney Int (1998) 1.71
Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature (1981) 1.70
The protofilament substructure of amyloid fibrils. J Mol Biol (2000) 1.69
Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology (1982) 1.67
Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol (2000) 1.66
Biology of serum amyloid P component. Ann N Y Acad Sci (1982) 1.65
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet (1988) 1.61
C-reactive protein in SLE. Clin Rheum Dis (1982) 1.61
Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia (1988) 1.60
Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J (2004) 1.59
Amyloid P-component is a constituent of normal human glomerular basement membrane. J Exp Med (1980) 1.57
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56
Fibronectin and C4-binding protein are selectively bound by aggregated amyloid P component. J Exp Med (1981) 1.53
Studies in vivo of cobra factor and murine C3. Immunology (1975) 1.49
Hormone binding globulins undergo serpin conformational change in inflammation. Nature (1988) 1.47
Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci U S A (2000) 1.47
Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. QJM (2000) 1.45
Differing acute phase responses in Crohn's disease and ulcerative colitis. Gut (1986) 1.44
Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology (Oxford) (2003) 1.43
Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet (1991) 1.42
An autosomal dominant periodic fever associated with AA amyloidosis in a north Indian family maps to distal chromosome 1q. Arthritis Rheum (2000) 1.41
C-reactive protein: binding to lipids and lipoproteins. Int Rev Exp Pathol (1985) 1.40
Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentration of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol (1982) 1.39
Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med (1984) 1.38
Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity. Clin Exp Immunol (1982) 1.37
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration. Clin Nephrol (1984) 1.36
Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation (1998) 1.36
Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A (1994) 1.35
Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A (1992) 1.35
Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation (1998) 1.35
Acute phase response and evolution of familial Mediterranean fever. Lancet (1999) 1.34
Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med (1988) 1.34